Phase III clinical trials for all three CDK4/6 inhibitors have been completed, and results consistently show that the addition of CDK4/6 inhibitors to endocrine therapy significantly prolongs progression-free survival (PFS) compared to endocrine therapy alone in patients with advanced ER+ breast cancer [104]. Here, ESR1 is linked to breast carcinoma.